Farihah Malik
Overview
Explore the profile of Farihah Malik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
17
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malik F, Easterbrook P, Indolfi G, Thorne C
Front Public Health
. 2025 Feb;
12:1504678.
PMID: 39917533
Background And Aims: There are gaps in knowledge about the values and preferences of healthcare workers (HCW) with respect to treatment of children and adolescents living with chronic hepatitis C...
2.
Hamada Y, Quartagno M, Malik F, Ntshamane K, Tisler A, Gaikwad S, et al.
Trop Med Int Health
. 2024 Jul;
29(9):768-780.
PMID: 39073229
Objective: To investigate the prevalence of non-communicable diseases among household contacts of people with tuberculosis. Methods: We conducted a systematic review and individual participant data meta-analysis. We searched Medline, Embase...
3.
Hamada Y, Quartagno M, Law I, Malik F, Bonsu F, Adetifa I, et al.
PLOS Glob Public Health
. 2024 Feb;
4(2):e0002596.
PMID: 38422092
Tuberculosis (TB) and non-communicable diseases (NCD) share predisposing risk factors. TB-associated NCD might cluster within households affected with TB requiring shared prevention and care strategies. We conducted an individual participant...
4.
Malik F, Crichton S, Plotnikova Y, Latysheva I, Samarina A, Pokorska-Spiewak M, et al.
Pediatr Infect Dis J
. 2024 Feb;
43(5):e155-e159.
PMID: 38315439
We evaluated the effectiveness and safety of direct-acting antivirals in adolescents with hepatitis C (HCV)/HIV coinfection using pooled individual patient-level data from 5 European cohorts. Of 122 participants in follow-up...
5.
Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, Lucenteforte E
Liver Int
. 2024 Jan;
44(3):663-681.
PMID: 38293756
Background And Aims: We evaluated the effectiveness and safety of pan-genotypic regimens, glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/daclatasvir (SOF/DCV) and other direct-acting antivirals (DAA) regimens for the treatment of hepatitis...
6.
Hamada Y, Quartagno M, Law I, Malik F, Bonsu F, Adetifa I, et al.
EClinicalMedicine
. 2023 Sep;
63:102191.
PMID: 37680950
Background: Non-communicable diseases (NCDs) and NCD risk factors, such as smoking, increase the risk for tuberculosis (TB). Data are scarce on the risk of prevalent TB associated with these factors...
7.
Malik F, Chulanov V, Pimenov N, Fomicheva A, Lundin R, Levina N, et al.
J Virus Erad
. 2022 Feb;
8(1):100063.
PMID: 35198235
Background: The Russian Federation has the largest paediatric hepatitis C virus (HCV) disease burden in the World Health Organization European region with an estimated 118,000 children living with HCV viraemia....
8.
Malik F, Malyuta R, Volokha A, Bailey H, Collins I, Thorne C
Pediatr Infect Dis J
. 2022 Jan;
41(5):417-419.
PMID: 35067642
Direct-acting antivirals (DAAs) have been approved for treating chronic hepatitis C virus (HCV) in children and adolescents. Although DAAs have been used in real-world settings for the treatment of HCV...
9.
Malik F, Bailey H, Chan P, Collins I, Mozalevskis A, Thorne C, et al.
JHEP Rep
. 2021 Mar;
3(2):100227.
PMID: 33665586
Background & Aims: It is estimated that 3.26 million children and adolescents worldwide have chronic HCV infection. To date, the global response has focused on the adult population, but direct-acting...